alpha-MSH analogue is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-11-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Synthetic cyclic heptapeptide |
| Molecular mass | Approximately 1024 g/mol | Depends on counter-ion content |
| Appearance | White to off-white powder | Commonly supplied as a lyophilised solid |
| Solubility | Freely soluble in water | Also dissolves in common aqueous buffers |
| Typical storage | -20 degrees Celsius, desiccated | Protect from light and repeated freeze-thaw |
Two structural changes distinguish the synthetic peptide from the natural hormone. A norleucine residue replaces methionine at one position, and a D-configured phenylalanine replaces the natural L-form at another. Both substitutions slow enzymatic breakdown, which extends the molecule's persistence relative to the parent hormone. The lactam bridge further constrains the backbone into a stable conformation. These features are standard design strategies in peptide chemistry and are not unique to this compound; they appear across many research peptides built for improved stability.
The compound was developed in the late 1980s and early 1990s by academic researchers investigating melanocortin signaling and pigmentation. Early work explored whether synthetic analogs could reproduce effects of the natural hormone under controlled conditions. The molecule never advanced through the full regulatory pathway required for approval as a medicine. From the mid-2000s onward it appeared in unregulated consumer markets, often distributed through informal channels. That gap between research origins and commercial availability shapes how the compound is discussed today.
Melanotan-2 is a synthetic peptide designed as an analog of alpha-melanocyte-stimulating hormone, a signaling molecule produced in the pituitary and skin. Its structure is a linear chain of seven amino acids that folds into a ring through an internal lactam bridge joining two side chains. The compound is sometimes written as MT-II or MEL-2 in informal and commercial contexts. It belongs to the melanocortin peptide family, a group of short signaling molecules that share a conserved core sequence recognized by melanocortin receptors.
Pellucid marginal degeneration (PMD) is a degenerative corneal condition, often confused with keratoconus. It typically presents with painless vision loss affecting both eyes. Rarely, it may cause acute vision loss with severe pain due to perforation of the cornea. It is typically characterized by a clear, bilateral thinning (ectasia) in the inferior and peripheral region of the cornea, although some cases affect only one eye. The cause of the disease remains unclear. Pellucid marginal degeneration is diagnosed by corneal topography. Corneal pachymetry may be useful in confirming the diagnosis. Treatment usually consists of vision correction with eyeglasses or contact lenses. Intacs implants, corneal collagen cross-linking, and corneal transplant surgery are additional options. Surgery is reserved for individuals who do not tolerate contact lenses. The term pellucid marginal degeneration was coined in 1957 by the ophthalmologist Schalaeppi. The word "pellucid" means clear, indicating that the corneas retain clarity in pellucid marginal degeneration. The condition is rare, though the exact prevalence and incidence are unknown.
Mitochondrial disease is a group of genetic disorders caused by mitochondrial dysfunction. Mitochondria are the organelles that generate energy for the cell and are found in every cell of the human body except red blood cells. They convert the energy of food molecules into the ATP that powers most cell functions. Mitochondrial diseases take on unique characteristics both because of the way the diseases are often inherited and because mitochondria are so critical to cell function. A subclass of these diseases that have neuromuscular symptoms are known as mitochondrial myopathies. Additionally, different paradigms like intermittent fasting can improve mitochondrial health and contribute in longevity.
Donald McKain, Staff Side Coordinator, Grampian Healthcare NHS Trust. For services to Health Care. Neil McKay, Revenue Executive, Board of Inland Revenue. Stuart William McKay. For services to the de Havilland Moth Club. Evelyn Hildegard McKinley, Administrative Officer, Ministry of Defence. Norman McLean, Director, National Mentoring Consortium. For services to the Ethnic Community. Richard Dick McLean, Prison Officer, Her Majesty's Prison, Edinburgh. Carol Ross McNeilage, Nursing Auxiliary, Vale of Leven Hospital, Alexandria. For services to Health Care and to the community. Valerie Matilda McNeill. For services to the Ports Industry. Paul McStay. For services to Association Football. Joseph Henry McWhirter. For services to the community and to the Post Office. Ivy Florence Medley. For services to the community in St Lawrence, Essex. Jeremiah Joseph Mee. For services to the Sick Dentist Scheme. David Klemman Meeker. For services to the National Film and Television Archive. Bridget Anne Meyer, Higher Executive Officer, Commonwealth War Graves Commission. Rolf Meyer. For services to the community in Brixham, Devon. Donald John Milburn. For services to the Police and to the community. Evelyn May Miller, Administrative Officer, Ministry of Defence. Nicholas Charles Miller. For services to People with Alcohol Problems. Sheila Denise Miller. For services to the British Tourist Authority. Squadron Leader Raymond Mills. For services to the community in Cambridgeshire. Ena Montgomery. For services to the community in Chorley, Lancashire. Robert Joseph Montgomery.
"[Nar]am-Sin, the mighty, <Lacuna> ..., Sidu[r-x] (and) the highlanders of Lullubum assembled together ... bat[tle]. For/to <Lacuna> the high[landers ...] <Lacuna> [heap]ed up [a burial mound over them], ... (and) dedicated (this object) [to the god ...] <Lacuna> Shutruk-Nahhunte added his own inscription to the stele, in Middle Elamite:
Wool Bradford, Halifax and Huddersfield grew through the development of woollen mills. Leeds' traditional industry was the manufacturing of cloth while heavier engineering industries facilitated growth in South Leeds. The Heavy Woollen District covered towns such as Dewsbury, Batley, Morley, Ossett, Cleckheaton and Heckmondwike. The woollen and cloth industries declined throughout the twentieth century.
Sources: en.wikipedia.org
In February 2015, the FDA reported about a transmission risk when people undergo a gastroenterology procedure called endoscopic retrograde cholangiopancreatography, where an endoscope enters the mouth, passes the stomach, and ends in the duodenum; if incompletely disinfected, the device can transmit CRE from one patient to another. The FDA's safety communication came a day after the UCLA Health System, Los Angeles, notified more than 100 patients that they may have been infected with CRE during endoscopies between October 2014 and January 2015. The FDA had issued its first notice about the devices in 2009.
==== Bicycle and pedestrian ==== The Maine-to-Florida U.S. Bicycle Route#1 routes through suburban Raleigh, along with N.C. Bicycle Route #2, the "Mountains To Sea" route. As of September 2010, maps and signage for both US Bike Route No. 1 and NC Bike Route No. 2 are out-of-date for the Raleigh area. N.C. Bicycle Route #5 is routed nearby, connecting Apex to Wilmington and closely paralleling the NCBC Randonneurs 600-kilometer brevet route. Most public buses are equipped with bicycle racks, and some roads have dedicated bicycle-only lanes. Bicyclists and pedestrians also may use Raleigh's extensive greenway system, with paths and trails located throughout the city. In May 2011, Raleigh was designated a Bicycle Friendly Community by the League of American Bicyclists at the Bronze level. In 2002, the "Walk [Your City]" initiative was started in the city which provides a tool kit for neighborhood organizations to post signs giving a distance by bike or foot, with directions in scannable QR code. The movement has spread to more than 400 communities in 55 countries.
==== MeSH D06.472.699 – peptide hormones ==== MeSH D06.472.699.009 – activins MeSH D06.472.699.009.500 – inhibin-beta subunits MeSH D06.472.699.054 – adiponectin MeSH D06.472.699.100 – bombesin MeSH D06.472.699.150 – calcitonin MeSH D06.472.699.200 – corticotropin-releasing hormone MeSH D06.472.699.275 – gastric inhibitory polypeptide MeSH D06.472.699.280 – gastrins MeSH D06.472.699.318 – glucagon precursors MeSH D06.472.699.318.249 – enteroglucagons MeSH D06.472.699.318.249.500 – glucagon-like peptide 1 MeSH D06.472.699.318.500 – glucagon MeSH D06.472.699.337 – inhibins MeSH D06.472.699.337.500 – inhibin-beta subunits MeSH D06.472.699.350 – insulin MeSH D06.472.699.350.408 – insulin, isophane MeSH D06.472.699.350.532 – insulin, long-acting MeSH D06.472.699.350.788 – proinsulin MeSH D06.472.699.350.788.250 – c-peptide MeSH D06.472.699.400 – leptin MeSH D06.472.699.500 – motilin MeSH D06.472.699.560 – msh release-inhibiting hormone MeSH D06.472.699.580 – msh-releasing hormone MeSH D06.472.699.584 – natriuretic peptides MeSH D06.472.699.584.500 – atrial natriuretic factor MeSH D06.472.699.584.625 – natriuretic peptide, brain MeSH D06.472.699.584.750 – natriuretic peptide, c-type MeSH D06.472.699.587 – pancreatic polypeptide MeSH D06.472.699.590 – parathyroid hormone MeSH D06.472.699.590.850 – teriparatide MeSH D06.472.699.591 – parathyroid hormone-related protein MeSH D06.472.699.592 – peptide phi MeSH D06.472.699.595 – peptide yy MeSH D06.472.699.600 – pituitary hormone release inhibiting hormones MeSH D06.472.699.620 – pituitary hormone-releasing hormones MeSH D06.472.699.631 – pituitary hormones MeSH D06.472.699.631.525 – pituitary hormones, anterior MeSH D06.472.699.631.525.343 – gonadotropins, pituitary MeSH D06.472.699.631.525.343.288 – follicle stimulating hormone MeSH D06.472.699.631.525.343.288.500 – follicle stimulating hormone, beta subunit MeSH D06.472.699.631.525.343.288.625 – follicle stimulating hormone, human MeSH D06.472.699.631.525.343.288.750 – glycoprotein hormones, alpha subunit MeSH D06.472.699.631.525.343.463 – luteinizing hormone MeSH D06.472.699.631.525.343.463.249 – glycoprotein hormones, alpha subunit MeSH D06.472.699.631.525.343.463.500 – luteinizing hormone, beta subunit MeSH D06.472.699.631.525.343.583 – menotropins MeSH D06.472.699.631.525.343.583.500 – urofollitropin MeSH D06.472.699.631.525.425 – growth hormone MeSH D06.472.699.631.525.425.875 – human growth hormone MeSH D06.472.699.631.525.525 – prolactin MeSH D06.472.699.631.525.690 – pro-opiomelanocortin MeSH D06.472.699.631.525.690.130 – corticotropin MeSH D06.472.699.631.525.690.130.050 – alpha-msh MeSH D06.472.699.631.525.690.130.200 – cosyntropin MeSH D06.472.699.631.525.690.480 – lipotropin MeSH D06.472.699.631.525.690.583 – melanocyte-stimulating hormones MeSH D06.472.699.631.525.690.583.050 – alpha-msh MeSH D06.472.699.631.525.690.583.075 – beta-msh MeSH D06.472.699.631.525.690.583.115 – gamma-msh MeSH D06.472.699.631.525.883 – thyrotropin MeSH D06.472.699.631.525.883.249 – glycoprotein hormones, alpha subunit MeSH D06.472.699.631.525.883.500 – thyrotropin, beta subunit MeSH D06.472.699.631.692 – pituitary hormones, posterior MeSH D06.472.699.631.692.433 – oxytocin MeSH D06.472.699.631.692.781 – vasopressins MeSH D06.472.699.631.692.781.100 – argipressin MeSH D06.472.699.631.692.781.100.250 – deamino arginine vasopressin MeSH D06.472.699.631.692.781.400 – lypressin MeSH D06.472.699.631.692.781.400.350 – felypressin MeSH D06.472.699.631.692.781.700 – ornipressin MeSH D06.472.699.631.692.881 – vasotocin MeSH D06.472.699.649 – placental hormones MeSH D06.472.699.649.367 – chorionic gonadotropin MeSH D06.472.699.649.367.125 – chorionic gonadotropin, beta subunit, human MeSH D06.472.699.649.367.562 – glycoprotein hormones, alpha subunit MeSH D06.472.699.649.451 – gonadotropins, equine MeSH D06.472.699.649.692 – placental lactogen MeSH D06.472.699.715 – relaxin MeSH D06.472.699.762 – resistin MeSH D06.472.699.810 – secretin MeSH D06.472.699.857 – somatostatin MeSH D06.472.699.905 – urotensins MeSH D06.472.699.952 – vasoactive intestinal peptide MeSH D06.472.699.976 – vasopressins MeSH D06.472.699.976.100 – argipressin MeSH D06.472.699.976.100.250 – deamino arginine vasopressin MeSH D06.472.699.976.400 – lypressin MeSH D06.472.699.976.400.350 – felypressin MeSH D06.472.699.976.700 – ornipressin
=== Familial hypercholesterolemia === The 1985 Nobel Prize for medicine went to two researchers for their work related to familial hypercholesterolemia, which causes large and rapid increases in cholesterol levels. Their research led to the development of statin drugs which are now commonly used to treat high cholesterol.
Sources: en.wikipedia.org
=== Interactions === If people are using sNRI drugs they should not take MAO inhibitors at the same time. That can increase the plasma concentration of NRIs in the body. Beware of taking atomoxetine in combination with:
=== Televisions === QLED TVs have been starting to include cadmium in construction. Some companies have been looking to reduce the environmental impact of human exposure and pollution of the material in televisions during production.
== Background == He received his medical degree in 1982 from the National Autonomous University of Mexico. After postdoctoral training at University of California, San Diego (UCSD) he became a tenure-track professor at UCSD's Department of Neuroscience, with a joint appointment in Pathology. He also directed the neuropathology core of the Shirley-Marcos Alzheimer's Disease Research Center at UCSD. He was appointed head of the U.S. National Institute on Aging's Division of Neuroscience in 2016. He has a prolific body of work — over 800 research papers, much of which is now under scrutiny for containing manipulated images to support different conclusions than the real data. In September 2024, the NIH released a statement that stated he was no longer serving in the role of Director of the Division of Neuroscience.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide and an analogue of alpha-melanocyte-stimulating hormone. The molecule is produced by chemical synthesis rather than extracted from a biological source.
It is shorter than the native hormone and carries a cyclic constraint that improves stability. These changes raise receptor potency and slow breakdown relative to the naturally occurring peptide.
Published accounts date its development to the 1980s, when researchers were generating analogues of melanocyte-stimulating hormone. That work aimed to produce more stable compounds for studying pigmentation biology.
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.